Whalesbook
US Supply Chain Overhaul
Novartis is aggressively reshaping its supply chain with a $23 billion commitment to build nine new US manufacturing facilities. This move is designed to counter potential US tariff threats, particularly under a future Trump administration, by bringing production closer to the domestic market.
Navigating Pricing and Tariffs
CEO Vas Narasimhan highlighted the clarity gained from Most Favoured Nation (MFN) drug pricing agreements. He described this clarity as a significant "de-risking event" for the pharmaceutical industry, effectively mitigating concerns over pricing strategies in the US. The investment in US facilities is intended to eliminate the impact of any new tariffs.
The Entresto Patent Cliff
Alongside easing regulatory risks, Novartis faces the significant challenge of its largest patent expiry for the heart drug Entresto. Narasimhan expressed confidence in the company's ability to continue sales growth through ongoing innovation and new product launches, despite this major upcoming competition from generics.
Technology and Deal-Making
To support its growth strategy and offset potential cost increases from reshoring, Novartis is heavily leveraging automation and artificial intelligence in its new US plants. This technological integration aims to reduce labor requirements significantly. Furthermore, mergers and acquisitions remain central to Novartis's plan to keep its innovation engine fueled, as it targets substantial revenue growth.